14-15th October, 2021
RIGHT Institute, The Kursaal, Besançon
Conference held on site
Access the 2 day conference programme.
Online registration is now open at a fee.
The latest information on the website dedicated to the event.
The combination of microtechnology with cell therapies has enabled the RIGHT institute to bring out flagship products like CAR-T cells. These innovations will be highlighted during the conference, since Besançon will welcome the biggest global player specialised in the development of innovative therapies, their production and their regulatory supervision.
Clinicians, scientists, industrial partners will in turn present their latest scientific progress on the development of CAR-T cells, stem cells or pluripotent cells, their transfer to clinical trials and the challenges of their industrial production.
This wide range of actors, from academic to private, local to international, will also give their vision of the use of innovative therapies in tomorrow's medicine. The "Innovative Therapies Days" will give a large part to exchanges between partners through an Exhibitor Village, B2B sessions and discussion times.
André Baruchel – Hôpital Robert-Debré (Paris, FR),
Annelise Bennaceur, INSERM U935 ESTeam,
University Paris Saclay (Paris, FR),
Christian Chabannon – Institut Paoli-Calmettes (Marseille, FR),
Bruno Dalle, Yposkesi (Corbeille-Essonnes, FR),
Stéphane Depil – Centre Léon Bérard (Lyon, FR),
John de Vos – INSERM U1183, IRMB (Montpellier, FR),
Emmanuel Donnadieu – INSERM, Institut Cochin (Paris, FR),
Nicolas Ferry (Paris, FR),
Jordan Gauthier – Fred Hutch CR (Seattle, USA),
Christian Jorgensen – INSERM U1183, IRMB (Montpellier, FR),
Jens Kastrup – Rigshospitalet (DK),
Nico Lachmann – Hannover Medical School (Hannover, DE),
Marcello Maresca, Astrazeneca (Södertälje, SW),
Suman Mitra – INSERM (Lille, FR),
Constance Perrot, EASE (Illkirch, FR),
Laurent Poirot – Cellectis (Paris, FR),
Georg Rauser, Miltenyi Biomedicine (Bergisch Gladbach, DE),
Isabelle Rivière – Memorial Sloan Kettering (New-York City, USA),
Marco Ruella – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA),
Pierre Tiberghien – EFS (Paris, FR),
Philippe Henon – Cellprothera ( Mulhouse, FR)
Mature companies (> 5 years old): 950¤
Emerging companies (< 5 years old) and SMEs (< 10 employees) : 650¤
Academic scientists / Clinicians: 475 ¤
Students: 150 ¤